Development of a floating dosage form of ranitidine hydrochloride by statistical optimization technique.
The objective of this study was to evaluate the effect of formulation variables on the release properties, floating lag time, and hardness, when developing floating tablets of Ranitidine hydrochloride, by the statistical optimization technique. The formulations were prepared based on 3(2) factorial design, with polymer ratio (HPMC 100 KM: Xanthan gum) and the amount of aerosil, as two independent formulation variables. The four dependent (response) variables considered were: percentage of drug release at the first hour, T(50%) (time taken to release 50% of the drug), floating lag time, and hardness of the tablet. The release profile data was subjected to a curve fitting analysis, to describe the release mechanism of the drug from the floating tablet. An increase in drug release was observed with an increase in the polymer ratio, and as the amount of aerosil increased, the hardness of the tablet also increased, without causing any change in the floating lag time. The desirability function was used to optimize the response variables, each having a different target, and the observed responses were in accordance with the experimental values. The results demonstrate the feasibility of the model in the development of floating tablets containing Ranitidine hydrochloride.
Department of Pharmaceutics, Government College of Pharmacy, No. 2, P. Kalinga Rao Road, Bangalore-560 027, India.
S
S
Jain
Ms
M
Srinath
C
C
Narendra
Sn
S
Reddy
A
A
Sindhu
Int J Pharm. 2004 Jun 11;277(1-2):141-53
15158977
Int J Pharm. 2005 Nov 4;304(1-2):102-14
16150561
J Control Release. 2000 Feb 3;63(3):235-59
10601721
Drug Dev Ind Pharm. 2000 Aug;26(8):857-66
10900542
AAPS PharmSciTech. 2004 Apr 08;5(2):e34
15760092
J Pharm Pharmacol. 1998 Feb;50(2):159-66
9530983
Pak J Pharm Sci. 2009 Apr;22(2):155-61
19339225
J Control Release. 2000 Feb 14;64(1-3):39-51
10640644
Int J Pharm. 2001 Oct 4;227(1-2):157-65
11564550
Crit Rev Ther Drug Carrier Syst. 1993;10(2):143-95
8370085
Drug Dev Ind Pharm. 1998 Nov;24(11):1067-72
9876561
Adv Drug Deliv Rev. 1998 Dec 1;34(2-3):191-219
10837678